JRCT ID: jRCT2080220050
Registered date:07/09/2005
Laforet study
Basic Information
| Recruitment status | |
|---|---|
| Health condition(s) or Problem(s) studied | Mild reflux esophagitis |
| Date of first enrollment | 07/09/2005 |
| Target sample size | |
| Countries of recruitment | |
| Study type | Interventional |
| Intervention(s) | investigational material(s) Generic name etc : Lafutidine INN of investigational material : lafutidine Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : lafutidine (20 mg/day) for 8 weeks control material(s) Generic name etc : Famotidine INN of investigational material : famotidine Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : famotidine (40 mg/day) for 8 weeks Generic name etc : Placebo INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material : placebo for 8 weeks |
Outcome(s)
| Primary Outcome | Endoscopic healing rate and incidence of adverse events. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | >= 20age old |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | 1) Age 20 and older at the time of consent given. 2) Patients diagnosed with Grade A or Grade B mild reflux oesophagitis according to the Los Angels classification through endoscopic test. |
| Exclude criteria |
Related Information
| Primary Sponsor | Taiho Pharmaceutical Co., Ltd. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Taiho Pharmaceutical Co.,Ltd. |
| Secondary ID(s) | JapicCTI-050050 |
Contact
| Public contact | |
| Name | |
| Address | toiawase@taiho.co.jp |
| Telephone | |
| Affiliation | Taiho Pharmaceutical Co.,Ltd. |
| Scientific contact | |
| Name | |
| Address | toiawaseCD1@taiho.co.jp |
| Telephone | |
| Affiliation | Taiho Pharmaceutical Co.,Ltd. |